Ditha Modritz

St Anna's Kinderspital, Wien, Vienna, Austria

Are you Ditha Modritz?

Claim your profile

Publications (4)1.63 Total impact

  • European Journal of Cancer - EUR J CANCER. 01/2011; 47.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the CWS 96 Study was to achieve an optimal treatment in children and adolescents with soft tissue sarcoma (STS) implementing a further refinement of risk-adapted allocation to chemotherapy, surgery and radiotherapy. Treatment stratification was based on tumour histology, TNM status, postsurgical stage, localisation and age. Local tumour control was ensured by surgery and risk-adapted radiotherapy. From 1995 to 2002, 89 patients were registered in Austria. The 3-year event-free survival (EFS) and overall survival rates (OS) were 63% +/- 6% and 71% +/- 6%, respectively. 59/89 patients had localised RMS-like (rhabdomayosarcoma) STS (EFS 73% +/- 7%), 14 had localised NON-RMS STS (EFS 54% +/- 16%) and 15 patients had metastatic disease at diagnosis (EFS 33% +/- 12%), 1 patient had fibromatosis. The EFS rates at 3 years in patients with localised RMS-like tumours according to risk group were 92% +/- 8% for low and standard risk (12 patients) and 67% +/- 8% for high risk (47 patients). Favourable primary tumour sites of nonmetastatic RMS-like STS i.e. orbit, head/neck nonparameningeal or genitourinary non-bladder/prostate were diagnosed in 15 patients (1/15 patients died). In 44 patients with unfavourable localisation such as parameningeal, genitourinary bladder/prostate, extremity and others, 7 deceased. The 3 year EFS according to histology in patients with RMS-like STS was 61% +/- 11% for RME (embryonal RMS ) (28 patients) and 71% +/- 15% for RMA (alveolar RMS) (10 patients). The most common treatment failure was local relapse occurring in 21% of patients in the high-risk group. Risk-adapted individualisation of treatment led to a reduction of chemotherapy in the low and standard risk group without compromising survival. The outcome of RME and RMA was similar in this cohort of patients. These preliminary results after a median observation time of 2.5 years confirm the CWS 96 strategy.
    Wiener klinische Wochenschrift 04/2005; 117(5-6):196-209. · 0.81 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE: The aim of the CWS 96 Study was to achieve an optimal treatment in children and adolescents with soft tissue sarcoma (STS) implementing a further refinement of risk-adapted allocation to chemotherapy, surgery and radiotherapy. METHODS: Treatment stratification was based on tumour histology, TNM status, postsurgical stage, localisation and age. Local tumour control was ensured by surgery and risk-adapted radiotherapy. RESULTS: From 1995 to 2002, 89 patients were registered in Austria. The 3-year event-free survival (EFS) and overall survival rates (OS) were 63% 6% and 71% 6%, respectively. 59/89 patients had localised RMS-like (rhabdomayosarcoma) STS (EFS 73% 7%), 14 had localised Non-RMS STS (EFS, 54% 16%) and 15 patients had metastatic disease at diagnosis (EFS, 33% 12%), 1 patient had fibromatosis. The EFS rates at 3years in patients with localised RMS-like tumours according to risk group were 92% 8% for low and standard risk (12 patients) and 67% 8% for high risk (47 patients). Favourable primary tumour sites of nonmetastatic RMS-like STS i.e. orbit, head/neck nonparameningeal or genitourinary non-bladder/prostate were diagnosed in 15 patients (1 of 15 patients died). In 44 patients with unfavourable localisation such as parameningeal, genitourinary bladder/prostate, extremity and others, 7 deceased. The 3-year EFS according to histology in patients with RMS-like STS was 61% 11% for RME (embryonal RMS ) (28 patients) and 71% 15% for RMA (alveolar RMS) (10 patients). The most common treatment failure was local relapse occurring in 21% of patients in the high-risk group. CONCLUSION: Risk-adapted individualisation of treatment led to a reduction of chemotherapy in the low- and standard-risk group without compromising survival. The outcome of RME and RMA was similar in this cohort of patients. These preliminary results after a median observation time of 2.5years confirm the CWS 96 strategy.ZIEL: Die CWS-96-Studie fr Behandlung von Weichteilsarkomen (WS) im Kindes- und Jugendalter verfolgte eine maximale Tumorkontrolle bei Minimierung von Sptfolgen durch eine verbesserte risikoadaptierte Chemo-, Operations- und Radiotherapie. METHODEN: Die Stratifikation der Patienten erfolgte nach Histologie, TNM-Status, postchirurgischem Stadium, Lokalisation und Alter. Die Lokalkontrolle wurde durch Chirurgie und risikoadaptierte Bestrahlung angestrebt. ERGEBNISSE: Im Zeitraum von 1995 bis 2002 wurden 89 Patienten registriert. Das ereignisfreie (EFS) und das absolute berleben (OS) nach 3 Jahren lag bei 63% 6% bzw. 71% 6%. 59 von 89 Patienten hatten lokalisierte RMS-(Rhabdomysoarkom-)artige WS (EFS, 73% 7%), 14 lokalisierte Non-RMS-artige WS (EFS, 54% 16%), 15 initial disseminierte WS (EFS, 33% 12%) und 1 Fibromatose. Das 3-Jahres-berleben bei lokalisierten RMS-artigen nach Risikogruppe ergab 92% 8% EFS fr niedriges und Standard-Risiko (12 Patienten), sowie 67% 8% EFS fr hohes Risiko (47 Patienten). Die Lokalisation der 59 nicht metastasierten RMS-artigen WS war bei 15 Patienten in als gnstig definierten Regionen (Orbita, Kopf/Hals – nicht parameningeal oder urogenital – nicht Blase/Prostata: 1 von 15 Patienten verstorben), whrend bei 44 Patienten ungnstige Lokalisationen vorlagen (Kopf/Hals – parameningeal, urogenital – Blase/Prostata, Extremitten und andere: 7 von 44 Patienten verstorben). Das EFS nach Histologie in der Kategorie der lokalisierten RMS-artigen lag fr embryonale RMS (RME) (28 Patienten) bei 61% 11% und fr alveolre RMS (RMA) (10 Patienten) bei 71% 15%. Das Hauptproblem war das lokale Rezidiv, das bei 21% aller Patienten im Hochrisikoarm auftrat. SCHLUSSFOLGERUNG: Die risikoadaptierte Individualisierung der Therapie als oberstes Ziel fhrte zu Einsparungen an Chemotherapie in der Niedrig- und Standard-Risiko-Gruppe bei erhaltener guter Prognose. In dieser Patientenkohorte war das berleben fr RME und RMA hnlich. Nach einer medianen Beobachtungszeit von 2,5 Jahren besttigen diese ersten Ergebnisse die erfolgreiche Umsetzung des CWS-Konzeptes.
    Wiener klinische Wochenschrift 02/2005; 117(5):196-209. · 0.81 Impact Factor
  • Wiener Klinische Wochenschrift - WIEN KLIN WOCHENSCHR. 01/2005; 117:196-209.